Terry Rosen, Arcus CEO

Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

Ar­cus’ small mol­e­cule CD73 in­hibitor for pan­cre­at­ic can­cer got a stand­ing ova­tion from an­a­lysts who said pre­lim­i­nary da­ta “ex­ceed­ed ex­pec­ta­tions”— mak­ing waves in a field that’s seen lit­tle progress in sev­er­al years and prov­ing the can­di­date could be worth the hun­dreds of mil­lions Gilead pro­vid­ed up­front in a deal that in­clud­ed more than a bil­lion dol­lars for opt-in rights and mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.